97 Results for "

IDH

" in MedChemExpress (MCE) Product Catalog:
Products (97)

97 Results for "IDH" in MCE Product Catalog:

20
20 Publications Verification
Cat. No.: HY-18082
CAS No.: 1355326-35-0
Synonyms: IDH-C35
Research Areas:  

Cancer

AGI-5198 (IDH-C35) is a potent and selective mutant IDH1 R132H inhibitor with an IC50 of 0.07 μM.
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-18690
CAS No.: 1446502-11-9
Synonyms: AG-221
Research Areas:  

Cancer

Enasidenib is an oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes, with IC50s of 100 and 400 nM against IDH2 R140Q and IDH2 R172K, respectively.
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-18690A
CAS No.: 1650550-25-6
Synonyms: AG-221 mesylate
Research Areas:  

Cancer

Enasidenib mesylate is a first-in-class, oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes.
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-N0328
CAS No.: 6147-11-1
Synonyms: α-Mangostin
alpha-Mangostin (α-Mangostin) is a dietary xanthone with broad biological activities, such as antioxidant, anti-allergic, antiviral, antibacterial, anti-inflammatory and anticancer effects. It is an inhibitor of mutant IDH1 (IDH1-R132H) with a Ki of 2.85 μM.
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-15734
CAS No.: 1432660-47-3
Purity:  99.26%
Research Areas:  

Cancer

AGI-6780 that potently and selectively inhibits the tumor-associated mutant IDH2 R140Q with IC50 of 23±1.7 nM. AGI-6780 is less potent against IDH2 WT with IC50 of 190±8.1 nM.
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-19540
CAS No.: 1816331-66-4
Research Areas:  

Cancer

GSK864, a chemical probe, is an isocitrate dehydrogenase 1 (IDH1) mutant inhibitor; inhibits IDH1 mutants R132C, R132H, and R132G with IC50 values of 8.8, 15.2 and 16.6 nM.
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-104042
CAS No.: 1644545-52-7
Purity:  99.87%
Synonyms: AG-881
Research Areas:  

Cancer

Vorasidenib (AG-881) is an orally available, brain penetrant second-generation dual mutant isocitrate dehydrogenases 1 and 2 (mIDH1/2) inhibitor. Vorasidenib (AG-881) exhibits nanomolar inhibition of (D)-2-hydroxyglutarate (D-2-HG), and the IC50 ranges of 0.04~22 nM against IDH1 R132C, IDH1 R132G, IDH1 R132H and IDH1 R132S and 7~14 nM against IDH2 R140Q and 130 nM against IDH2 R172K. Vorasidenib can be used for the study of grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1/2 mutation .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-104036
CAS No.: 1628805-46-8
Purity:  98.75%
Research Areas:  

Cancer

IDH-305 is an orally available, mutant-selective and brain-penetrant IDH1 inhibitor that targets IDH1 (R132) mutation. IDH-305 exhibits greater than 200 fold selectivity for mutant IDH1 isoforms vs. WT (IC50= 27 nM (IDH1 R132H), 28 nM (IDH1 R132C), 6.14 µM (IDH1 WT)) .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-128661
CAS No.: 2244895-42-7
Purity:  99.40%
Research Areas:  

Metabolic Disease

IDH1 Inhibitor 2 (compound 13) is a potent wild-type IDH1 inhibitor that exerts its activity through covalent modification of His315 with an IC50 value of 110 nM. IDH1 Inhibitor 2 can dose-dependently reduce the intracellular reduced glutamine metabolic flux, thereby affecting cellular metabolic homeostasis. IDH1 Inhibitor 2 can be used to study the role of IDH1 in cellular metabolic regulation and cancer development .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-114226
CAS No.: 1887014-12-1
Purity:  99.16%
Synonyms: FT-2102
Olutasidenib (FT-2102) is a highly potent, orally active, brain penetrant and selective inhibitor of mutant Isocitrate dehydrogenase 1 (IDH1), with IC50 values of 21.2 nM and 114 nM for IDH1- R132H and IDH1- R132C, respectively . Olutasidenib (FT-2102) is under the study in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-100020
CAS No.: 1803274-65-8
Purity:  99.79%
Research Areas:  

Cancer

BAY-1436032 is a novel pan-mutant isocitrate dehydrogenase 1 (IDH1) inhibitor.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-129545
CAS No.: 1898207-64-1
Purity:  99.71%
Research Areas:  

Cancer

DS-1001b is an orally active, blood-brain permeable, potent IDH-1 (isocitrate dehydrogenase-1) mutant inhibitor. DS-1001b has antitumor activity .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-12475
CAS No.: 1355326-21-4
Purity:  99.43%
Synonyms: Agios 135
Research Areas:  

Cancer

Mutant IDH1-IN-1 (Agios 135) is a selective mutant IDH1 inhibitor with activity against both IDH1 R132H and IDH1 R132C. Mutant IDH1-IN-1 reduces the level of 2-hydroxyglutarate (2-HG), stabilizes mutant IDH1 protein, and restores blocked monocyte differentiation. Mutant IDH1-IN-1 can be used in tumor-related research .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-145594
CAS No.: 1898206-17-1
Synonyms: AB-291; DS-1001
Research Areas:  

Cancer

Safusidenib (AB-291; DS-1001) is an orally bioavailable, selective mutant IDH1 inhibitor. Safusidenib strongly inhibits mutant IDH1 but not wild-type IDH1. Safusidenib impairs tumor activity in chondrosarcoma . Safusidenib exhibits activity against IDH1R132H, and IDH1R132C with IC50s of 15, and 130 nM in assays without any preincubation, respectively .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-13972
CAS No.: 1429180-08-4
Purity:  99.40%
Research Areas:  

Cancer

Mutant IDH1 inhibitor is a potent mutant IDH1 R132H inhibitor with IC50 of < 72 nM.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-18717
CAS No.: 1429176-69-1
Research Areas:  

Cancer

Mutant IDH1-IN-2 is a inhibitor of mutant Isocitrate dehydrogenase (IDH) proteins, with IC50 of in LS-MS biochemical assay, IC50 of 16.6 nM in Fluorescence biochemical assay.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-18948
CAS No.: 1816331-63-1
Research Areas:  

Cancer

GSK321 is a potent, selective mutant IDH1 inhibitor with IC50 values of 2.9, 3.8, 4.6 and 46 nM for R132G, R132C, R132H and WT IDH1, respectively, and >100-fold selectivity over IDH2. GSK321 induces decrease in intracellular α-Hydroxyglutaric acid (2-HG) (HY-113038B), abrogation of the myeloid differentiation block and induction of granulocytic differentiation at the level of leukemic blasts and more immature stem-like cells. GSK321can be used for research of acute myeloid leukemia (AML) and other cancers .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-112056
CAS No.: 151358-48-4
Purity:  99.47%
DIM-C-pPhCO2Me is a nuclear receptor 4A1 (NR4A1) antagonist. DIM-C-pPhCO2Me induces Apoptosis. DIM-C-pPhCO2Me decreases PAX3-FOXO1A, N-Myc, Rassf4, MyoD1, Grem1, and DAPK1 proteins. DIM-C-pPhCO2Me decreases expression of TXNDC5 and IDH1, induces markers of ER stress (CHOP, ATF4 and p-PERK). DIM-C-pPhCO2Me inhibits renal cell carcinoma, breast cancer. DIM-C-pPhCO2Me can also be used in rhabdomyosarcoma research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P80995

Host:  

Rabbit

Application:  

WB, IHC-P, IP

Reactivity:  

Human, Mouse, Rat

loading...
    loading...
Cat. No.: HY-18767A
CAS No.: 2070009-31-1
Synonyms: (R,S)-AG-120
(R,S)-Ivosidenib ((R,S)-AG-120) is a (R,S)-enantiomer of Ivosidenib (AG-120) with lower activity. Ivosidenib can be used in research on IDH1-mutant cancers .
loading...
    loading...